Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• Discontinuation of Antihypertensive Drugs For AEs Vary By Drug Class, Regimen
  A network meta-analysis of the discontinuation of blood-pressure (BP)-lowering medications due to adverse drug effects (AEs) found that the best-tolerated treatment was a combination of an angiotensin receptor blocker (ARB) and calcium channel blocker (CCB), with four of the top five best-tolerated regimens containing ARBs...
• Five-Decade Cohort Study: Adolescent Cardiorespiratory Fitness Brings Long-Term CV Benefit
  A high level of cardiorespiratory fitness (CRF) among adolescents was associated with a small excess risk of atrial fibrillation (AFib) during early adulthood – but this was outweighed by larger reductions in non-AFib cardiovascular disease later in life and after controlling for familial cofounders...
• New Studies Point to Emerging Strategies For HFrEF, Familial Hypercholesterolemia
  Results from two early studies published in NEJM could have important implications for patients with heart failure (HF) and reduced LVEF and for adults with heterozygous familial hypercholesterolemia (HFH) or premature coronary artery disease, respectively.
• Eagle’s Eye View: ED Patients With ‘Low Risk’ Chest Pain Often Deferred Future Testing
  In this week’s View, Dr. Eagle looks at recent research found in ACC’s new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining ‘low risk’ chest pain and its evaluation in the emergency departments.
• FLOW Analysis: Semaglutide Delivers Consistent Kidney Benefit in T2D/CKD Across CVD Status
  Semaglutide improved kidney and survival outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), including those with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and high total cardiovascular disease risk, according to a subgroup analysis of the FLOW trial...